国产精品一区二区av麻豆,国产成人综合色视频精品,亚洲伊人成综合网2222,国产凸凹视频一区二区

衰老關(guān)鍵蛋白3(FBLN3)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法)

CLIA Kit for Fibulin 3 (FBLN3)

EFEMP1; DHRD; DRAD; FBNL; MLVT; MTLV; S1-5; EGF-Containing Fibulin-Like Extracellular Matrix Protein 1; Fibrillin-Like; Extracellular protein S1-5

  • 衰老關(guān)鍵蛋白3(FBLN3)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法)產(chǎn)品包裝(模擬)
  • 衰老關(guān)鍵蛋白3(FBLN3)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法)產(chǎn)品包裝(模擬)
  • 衰老關(guān)鍵蛋白3(FBLN3)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法)實(shí)驗(yàn)結(jié)果圖
  • SCF422Hu.jpg標(biāo)準(zhǔn)曲線圖
  • Certificate通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證

特異性

本試劑盒用于檢測(cè)衰老關(guān)鍵蛋白3(FBLN3)，經(jīng)檢測(cè)與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。

回收率

分別于定值血清及血漿樣本中加入一定量的衰老關(guān)鍵蛋白3(FBLN3)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。

樣本回收率范圍(%)平均回收率(%)
serum(n=5)96-105101
EDTA plasma(n=5)98-105102
heparin plasma(n=5)86-10191

精密度

精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%

線性

在定值血清及血漿樣本內(nèi)加入適量的衰老關(guān)鍵蛋白3(FBLN3)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中衰老關(guān)鍵蛋白3(FBLN3)含量的測(cè)定值與理論值的比率。

樣本1:21:41:81:16
serum(n=5)79-95%98-105%90-101%86-97%
EDTA plasma(n=5)91-99%97-105%88-102%86-99%
heparin plasma(n=5)80-101%84-94%98-105%87-98%

穩(wěn)定性

經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。

實(shí)驗(yàn)流程

1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100μL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加底物100µL，37°C孵育10分鐘；
8. 讀數(shù)。

實(shí)驗(yàn)原理

將衰老關(guān)鍵蛋白3(FBLN3)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的衰老關(guān)鍵蛋白3(FBLN3)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的衰老關(guān)鍵蛋白3(FBLN3)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入底物。加入底物后會(huì)產(chǎn)生輝光型光信號(hào)。發(fā)射光強(qiáng)度和樣品中的衰老關(guān)鍵蛋白3(FBLN3)呈正相關(guān)。用化學(xué)發(fā)光儀測(cè)定相對(duì)光單位（RLU），計(jì)算樣品濃度。

相關(guān)產(chǎn)品

編號(hào)適用物種：Homo sapiens (Human，人)應(yīng)用(僅供研究使用，不用于臨床診斷！)
RPF422Hu02衰老關(guān)鍵蛋白3(FBLN3)重組蛋白Positive Control; Immunogen; SDS-PAGE; WB.
RPF422Hu01衰老關(guān)鍵蛋白3(FBLN3)重組蛋白Positive Control; Immunogen; SDS-PAGE; WB.
PAF422Hu01衰老關(guān)鍵蛋白3(FBLN3)多克隆抗體WB; IHC; ICC; IP.
PAF422Hu02衰老關(guān)鍵蛋白3(FBLN3)多克隆抗體WB
LAF422Hu71衰老關(guān)鍵蛋白3(FBLN3)多克隆抗體(生物素標(biāo)記)WB; IHC; ICC.
MAF422Hu23衰老關(guān)鍵蛋白3(FBLN3)單克隆抗體WB
MAF422Hu24衰老關(guān)鍵蛋白3(FBLN3)單克隆抗體WB
MAF422Hu22衰老關(guān)鍵蛋白3(FBLN3)單克隆抗體WB
MAF422Hu25衰老關(guān)鍵蛋白3(FBLN3)單克隆抗體WB
MAF422Hu21衰老關(guān)鍵蛋白3(FBLN3)單克隆抗體WB
SEF422Hu衰老關(guān)鍵蛋白3(FBLN3)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)Enzyme-linked immunosorbent assay for Antigen Detection.
SCF422Hu衰老關(guān)鍵蛋白3(FBLN3)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法)Chemiluminescent immunoassay for Antigen Detection.
LMF422Hu衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)FLIA Kit for Antigen Detection.

參考文獻(xiàn)

雜志參考文獻(xiàn)
1Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma[PubMed: PMC3761217]
Anticancer Res. YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis.[Pubmed: 24324091]
Oncology ReportsRole of fibulin-3 in lung cancer: In vivo and in vitro analyses[Spandidos-publications: Source]
Current Pulmonology ReportsDiscovery of new biomarkers for malignant mesothelioma[Springer:Source]
United States Patent Application 20140378336DIAGNOSIS OF CELL PROLIFERATIVE DISEASES[Freepatentsonline:Source]
Thorax.Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma[Pubmed:Pmc4174124]
Egyptian Journal of Chest Diseases and TuberculosisValue of plasma and pleural effusion fibulin-3 levels in the diagnosis of malignant pleural mesothelioma effusions[Pubmed:23050525]
Radiol OncolFibulin-3 as a biomarker of response to treatment in malignant mesothelioma[PubMed: 26401134]
British Journal of Cancer Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis[PubMed: 26263483]
J Thorac Oncol.Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.[Pubmed:26903362]
BMJ OpenDiagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study [pubmed:27884852]
25HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients[pubmed:26733616]
BMJ JournalsDiagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational …[e013324.abstract]
Anticancer Res.Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.[pubmed:28314308]
Dis Markers.A Novel Panel of Serum Biomarkers for MPM Diagnosis.[pubmed:28348450]
The KneeAssociation of fibulin-3 concentrations with the presence and severity of knee osteoarthritis: A cross-sectional study[pubmed:29195846]
Disease markersPlasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population[pubmed:29200597]
Molecular?Medicine?ReportsPlacental protein 14 as a potential biomarker for diagnosis of preterm premature rupture of membranes[Pubmed:29749501]
OncotargetThe matrix protein Fibulin-3 promotes KISS1R induced triple negative breast cancer cell invasion[Pubmed:30046386]
Advances in?Clinical?and Experimental?MedicineFibulin-3 and other cartilage metabolism biomarkers in relationship to calprotectin (MRP8/14) and disease activity in rheumatoid arthritis patients treated with?…[68362.pdf]
PLoS OnePrediction of pneumoconiosis by serum and urinary biomarkers in workers exposed to asbestos-contaminated minerals[Pubmed: 30946771]